AES 005

Drug Profile

AES 005

Alternative Names: AES-005; AVI-005

Latest Information Update: 19 May 2009

Price : $50

At a glance

  • Originator Synageva BioPharma
  • Class Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 19 May 2009 Discontinued - Phase-I for Infections in USA (SC)
  • 30 Sep 2008 AES 005 is available for licensing and/or co-development in the USA (http://www.synageva.com)
  • 30 Jun 2005 AVI 005 is available for partnering (http://www.avigenics.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top